Related Experiment Video
Updated: Jul 10, 2026

An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
Advancing perspectives on proliferative vitreoretinopathy: Updates in experimental research and emerging clinical
Fang Zheng1, Elie Motulsky2, Luiz Roisman3
1Eye Center, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China; Singapore Eye Research Institute and Singapore National Eye Centre, The Academia, 20 College Road, Singapore.
Abstract:
Proliferative vitreoretinopathy (PVR) remains a major barrier in vitreoretinal surgery, being the leading cause of recurrent retinal detachment and surgical failure. PVR arises from abnormal wound healing, involving epithelial-mesenchymal transition (EMT) of retinal pigment epithelial cells, hyalocytes trans-differentiation into myofibroblasts, and dysregulated interactions among cytokines, growth factors, and chemokines. These lead to extracellular matrix remodeling and contractile membrane formation. Recent advancements have deepened insight into disease mechanisms and supported preclinical testing of therapies. Despite surgical progress, adjunctive treatments such as corticosteroids, antimetabolites, retinoids, and biologics show limited and inconsistent benefits in clinical trials. Emerging tools like proteomic biomarkers and advanced imaging offer promise for early risk detection and personalized care. However, major challenges remain in understanding disease complexity and improving tailored treatment outcomes. This review emphasizes the urgent need for targeted molecular therapies. Bridging basic science with clinical innovation will be key to advancing PVR management and preserving vision.
More Related Videos
Related Concept Videos
Glaucoma: Overview
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy

